Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429685 | 0.84 | GCGR (0.57) | GCGRADORA1SCN9A | |
| SCHEMBL7921907 | 0.83 | ADORA1 (0.46) | GCGRADORA1SCN9A | |
| SCHEMBL10129253 | 0.80 | GCGR (0.45) | GCGR | |
| SCHEMBL27633941 | 0.79 | ADORA1 (0.43) | GCGRADORA1SCN9A | |
| SCHEMBL527760 | 0.78 | ADORA1 (0.49) | GCGRADORA1SCN9A | |
| SCHEMBL2340032 | 0.77 | ADORA1 (0.48) | GCGRADORA1SCN9A | |
| SCHEMBL2344474 | 0.77 | ADORA1 (0.48) | GCGRADORA1SCN9A | |
| SCHEMBL2340089 | 0.77 | ADORA1 (0.48) | GCGRADORA1SCN9A | |
| SCHEMBL17875114 | 0.77 | ADORA1 (0.41) | GCGRADORA1SCN9A | |
| SCHEMBL3082 | 0.76 | ADORA1 (0.45) | GCGRADORA1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| EP-2598484-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK Pharmaceuticals d.d. (SI) | 2013-06-05 | — | — | EP | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | GCGR 2328/4885ADORA1 2992/4885SCN9A 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.